Bausch Health Companies Inc. Available-for-sale Securities
Bausch Health Companies Inc. (BHC) had Available-for-sale Securities of $0 as of 2013-12-31, per its 10-K filed 2014-02-28.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecurities · last filed 2014-02-28
- 2013-12-31: Available-for-sale Securities $0.00.
- 2013-09-30: Available-for-sale Securities $0.00.
- 2012-12-31: Available-for-sale Securities $11.58M.
| Period end | Available-for-sale Securities |
|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-28 |
| 2013-09-30 | $0.00 10-Q · filed 2013-11-01 |
| 2012-12-31 | $11.58M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |